41 related articles for article (PubMed ID: 21926922)
1. Luteinizing hormone-releasing hormone receptor antagonist may reduce postmenopausal flushing.
van Gastel P; van der Zanden M; Telting D; Filius M; Bancsi L; de Boer H
Menopause; 2012 Feb; 19(2):178-85. PubMed ID: 21926922
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone-releasing hormone and postmenopausal flushing.
de Boer H; van Gastel P; van Sorge A
N Engl J Med; 2009 Sep; 361(12):1218-9. PubMed ID: 19759388
[No Abstract] [Full Text] [Related]
3. Stellate-ganglion block as a treatment for severe postmenopausal flushing.
van Gastel P; Kallewaard JW; van der Zanden M; de Boer H
Climacteric; 2013 Feb; 16(1):41-7. PubMed ID: 23017097
[TBL] [Abstract][Full Text] [Related]
4. Soy germ isoflavones improve menopausal symptoms but have no effect on blood lipids in early postmenopausal Chinese women: a randomized placebo-controlled trial.
Ye YB; Wang ZL; Zhuo SY; Lu W; Liao HF; Verbruggen M; Fang S; Mai HY; Chen YM; Su YX
Menopause; 2012 Jul; 19(7):791-8. PubMed ID: 22278344
[TBL] [Abstract][Full Text] [Related]
5. A short study in the treatment of hot flashes with buccal administration of 17-beta estradiol.
Gass MS; Rebar RW; Cuffie-Jackson C; Cedars MI; Lobo RA; Shoupe D; Judd HL; Buyalos RP; Clisham PR
Maturitas; 2004 Oct; 49(2):140-7. PubMed ID: 15474758
[TBL] [Abstract][Full Text] [Related]
6. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase.
Sagnella F; Apa R; Guido M; Villa P; Spadoni V; Miceli F; Lanzone A
Fertil Steril; 2009 May; 91(5):1857-63. PubMed ID: 18538325
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
Comaru-Schally AM; Brannan W; Schally AV; Colcolough M; Monga M
J Clin Endocrinol Metab; 1998 Nov; 83(11):3826-31. PubMed ID: 9814453
[TBL] [Abstract][Full Text] [Related]
9. The menopausal hot flush--anything new?
Sturdee DW
Maturitas; 2008 May; 60(1):42-9. PubMed ID: 18384981
[TBL] [Abstract][Full Text] [Related]
10. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
[TBL] [Abstract][Full Text] [Related]
11. Effects of cetrorelix, a GnRH-receptor antagonist, on gonadal axis in women with functional hypothalamic amenorrhea.
Berardelli R; Gianotti L; Karamouzis I; Picu A; Giordano R; D'Angelo V; Zinnà D; Lanfranco F; Ghigo E; Arvat E
Gynecol Endocrinol; 2011 Oct; 27(10):753-8. PubMed ID: 21204607
[TBL] [Abstract][Full Text] [Related]
12. Ability of an anti-luteinizing hormone-releasing hormone vaccine to inhibit gonadotropins in postmenopausal women.
Gual C; Garza-Flores J; Menjivar M; Gutierrez-Najar A; Pal R; Talwar GP
Fertil Steril; 1997 Feb; 67(2):404-7. PubMed ID: 9022624
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women.
Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Niebch G; Derendorf H
Clin Pharmacol Ther; 2000 Dec; 68(6):617-25. PubMed ID: 11180022
[TBL] [Abstract][Full Text] [Related]
14. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
Reed SD; Newton KM; LaCroix AZ; Grothaus LC; Grieco VS; Ehrlich K
Menopause; 2008; 15(1):51-8. PubMed ID: 18257142
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone receptor gene expression during pubertal development of male rats.
Zapatero-Caballero H; Sanchez-Franco F; Guerra-Perez N; Fernandez-Mendez C; Fernandez-Vazquez G
Biol Reprod; 2003 May; 68(5):1764-70. PubMed ID: 12606421
[TBL] [Abstract][Full Text] [Related]
16. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
[TBL] [Abstract][Full Text] [Related]
18. [Changes of plasma serotonin precursor metabolite concentrations in postmenopausal women with hot flushes].
Chen Y; Lü X; Huang Y; Xin X; Ye X
Zhonghua Fu Chan Ke Za Zhi; 2002 Dec; 37(12):726-8. PubMed ID: 12622915
[TBL] [Abstract][Full Text] [Related]
19. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
20. Cetrorelix suppression test to assess the source of androgen overproduction in postmenopausal hirsutism.
de Boer H; de Man M; de Bruyn K; van Sorge A
Eur J Endocrinol; 2006 Sep; 155(3):391-3. PubMed ID: 16914592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
